美国养老院居民接种mRNA SARS-CoV-2疫苗后的不良事件监测
本研究利用美国最大养老院连锁机构的电子健康记录数据,前瞻性监测养老院居民接种mRNA新冠疫苗后的不良事件。截至2021年1月3日,8553名居民接种第一剂,至2021年2月20日8371名居民接种第二剂,另纳入11072名未接种居民作为对照。未发现神经系统结局、过敏反应或心脏事件存在显著关联。
要点
- 养老院居民接种mRNA新冠疫苗后,未发现神经系统、过敏反应或心脏事件的显著关联。
- 监测基于电子健康记录每日更新,覆盖147家接种机构与137家对照机构。
- 结论支持该人群接种mRNA疫苗的安全性,但需持续监测。
研究设计与样本
- 前瞻性监测研究,使用Genesis HealthCare的电子健康记录数据,每日更新疫苗接种与预设不良事件。
- 对照组为137家至少延迟15天启动接种的养老院中同期未接种居民,共11072人。
主要发现
- 未发现神经系统结局、过敏反应或心脏事件与疫苗接种存在显著关联。
临床怎么用
- 监测结果可为养老院居民接种mRNA新冠疫苗的安全性提供参考,支持在该人群中继续推进接种。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The devastating impact of the SARS-CoV-2 pandemic prompted the development and emergency use authorization of two mRNA vaccines in early 2020. Vaccine trials excluded nursing home (NH) residents, limiting adverse event data that directly apply to this population. METHODS: To prospectively monitor for potential adverse events associated with vaccination, we used Electronic Health Record (EHR) data from Genesis HealthCare, the largest NH provider in the United States. EHR data on vaccinations and pre-specified adverse events were updated daily and monitored for signal detection among residents of 147 facilities who received the first dose of vaccine between December 18, 2020 and January 3, 2021. For comparison, unvaccinated residents during the same time period were included from 137 facilities that started vaccinating at least 15 days after the vaccinating-facilities. RESULTS: As of January 3, 2021, 8553 NH residents had received one dose of SARS-CoV-2 vaccine and by February 20, 2021, 8371 residents had received their second dose of vaccine; 11,072 were included in the unvaccinated comparator group. No significant associations were noted for neurologic outcomes, anaphylaxis, or cardiac events. CONCLUSIONS: No major safety problems were detected following the first or second dose of the vaccine to prevent COVID-19 in the study cohort from December 18, 2020 through March 7, 2021.
引用
- Bardenheier BH, Gravenstein S, Blackman C, et al. Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. Vaccine. 2021. PMID: 34092431. doi:10.1016/j.vaccine.2021.05.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。